Republican Senators Question FDA on Abortion Pill Safety

On Wednesday, several Republican senators criticized the Food and Drug Administration (FDA) for allegedly broadening access to abortion pills without adequate oversight. They urged the agency to reinforce safety regulations and reassess its partnerships concerning these medications.

During a conference call, Senators Josh Hawley from Missouri and Bill Cassidy from Louisiana articulated their concerns, expressing disappointment that the FDA had not updated safety standards for abortion pills. Instead, it appears that the agency is forming collaborations with manufacturers of drugs used for chemical abortions.

“I’m asking the FDA to follow the science and reinstate the necessary safety barriers,” Hawley stated. He mentioned that the public has a right to clarification on these issues.

The senators’ remarks highlight that abortion policy remains a significant concern for some Republicans, despite President Donald Trump’s previous comments about leaving such matters to state authorities. Both Hawley and Cassidy expressed skepticism about the safety and usage rates of chemical abortions.

Interestingly, earlier this year, Republicans enacted a temporary ban on Medicaid funding for nonprofit organizations providing abortions as part of the One, Big Beautiful Bill Act.

This legislation hasn’t deterred Hawley and others from criticizing the FDA for partnering with Evita Solutions to create a new version of mifepristone, a prominent abortion drug. “I was frustrated to learn about the FDA approving yet another generic form of misoprostol,” Cassidy remarked, questioning the agency’s reasoning behind this decision.

Cassidy, along with 17 other Republican senators, sent a letter to the FDA earlier this month, seeking explanations for the approval of this new abortion pill. They expect responses by October 30th, but Cassidy pointed out that they hadn’t received any feedback yet, likely due to the government shutdown.

Without mifepristone and misoprostol, many abortions in the U.S. would be impossible. These compounds play a crucial role in terminating pregnancies by inducing the body to expel pregnancy tissue. According to the Guttmacher Institute, a research organization focused on reproductive rights, mifepristone accounted for 63% of all abortions in the United States in 2023.

“This is appalling,” Hawley said in a recent post, expressing concern over the FDA’s approval of a new chemical abortion drug amidst growing evidence that these medications pose serious risks to mothers. Naturally, the implications for the fetus are even more dire.

Hawley stated that 11% of women using chemical abortions faced some sort of health risk. “This data is pivotal. We’ve conducted one of the largest studies on chemical abortion claims based on insurance data,” he mentioned, referencing a study analyzing 865,000 insurance claims published over the summer.

In April, a study discussed serious side effects tied to medical abortions. The Center for Ethics and Public Policy found that these risks were 22 times higher than what the FDA label suggested. “It’s a straightforward way of saying they’re in serious danger,” Hawley indicated.

However, critics argue that the study lacks context and may ignore other complex factors. Marjorie Dannenfelser, president of the anti-abortion group Susan B. Anthony Pro-Life America, echoed Hawley’s concerns regarding pill safety. She views abortion pills as an easily accessible option, even in states with stringent abortion laws.

“This abortion pill is a means to push back against state sovereignty; state laws are being breached. The availability of abortion pills has led to increased abortion rates since the Dobbs decision,” she noted, referring to the 2022 case that removed federal protections for abortion.

Susan B. Anthony Pro-Life America has been a significant force behind Republican initiatives to limit Medicaid funding for abortion access through Trump’s One, Big Beautiful Bill Act.

Opponents of abortion are particularly focused on mifepristone access as a way to sustain their campaign against abortion, especially since the FDA allowed for remote prescriptions in response to the COVID-19 pandemic.

In June, the Supreme Court dismissed a challenge regarding the FDA’s 2001 approval of mifepristone, which claimed it bypassed safety requirements. Following this ruling, mifepristone continues to be widely accessible, though the door remains open for future legal challenges regarding the FDA’s authorization of the drug.

Like other chemical abortion critics, Hawley advocated for an independent review of the safety and reliability of abortion pills. He stressed the importance of reestablishing the historical safety protocols tied to mifepristone.

The FDA has yet to respond to requests for comments regarding these allegations.